Here’s what UK shares Manolete Partners and Marlowe reported today

The Marlowe and Manolete Partners share prices are edging higher in midweek business. Here’s why these UK shares are rising again.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

These two UK shares released all-new trading statements on Wednesday. Here’s the key information investors need to know.

A rising UK share

Shares in insolvency litigation specialist Manolete Partners (LSE: MANO) have halved in value over the past 12 months. This is because a strong economic recovery in the UK, and significant government support to ailing businesses, has hit the number of new cases experienced by the firm.

But Manolete’s share price edged 1% higher on Wednesday following the publication of full-year financials.  Revenues soared 49% during the financial year to March, to £27.8m. Meanwhile, Manolete’s retailed share of gross cash from completed cases rocketed 113% to £6.8m. And the UK legal share completed on a record 135 insolvency cases last year. It made 198 new case investments too, another all-time record.

The impact of that government assistance, along with increased staffing costs and a reassessment of the value of in-process cases during the pandemic, caused pre-tax profit to slump 26% to £7m. But Manolete expects the number of cases to rise as Covid-19 lockdown measures are rolled back and the government’s emergency suppression of insolvencies ends in September.

With the widely reported large backlog of insolvency cases, we expect new case enquiries to increase over the foreseeable future and we will continue working hard to deliver outstanding returns to both the creditors of insolvent estates and our investors,” Manolete commented.

Good momentum

The Marlowe (LSE: MRL) share price has fared much better than Manolete Partners during the past 12 months. The UK health and safety share has ballooned almost 80% in value as its aggressive approach to M&A has paid off. The business rose 1% on Wednesday too following the release of its own full-year financials.

Revenues rocketed 15% year-on-year during the 12 months to March, to £192m. And margins rose to 16.2%, from 13.1% previously. This was thanks to the positive impact of acquisitions, steps taken to improve productivity, and the leveraging its back-office infrastructure. All this meant that pre-tax profit soared 31% over the period to £17.1m.

Marlowe – which provides safety and compliance software and services — noted too that current 12-month run-rate revenues sit at £280m, 83% of which is recurring in nature. The company made 15 acquisitions in total last year and has continued spending heavily on M&A to supercharge future earnings growth. It’s made a further eight acquisitions since April to improve its presence in key markets.

Today, Marlowe affirmed its plan to generate run-rate revenues of £500m and adjusted EBITDA of £100m by financial 2024. The UK share said it hopes to achieve this “through deepening our market share across our sectors, broadening our activities across the business-critical arena, strengthening our business via operational improvements and delivering on our digital strategy.

And for the current financial year? Marlowe said it’s enjoyed a “strong start” with “good” levels of organic growth in the high-single-digit percentages across its businesses.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Marlowe. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »